Integra Lifesciences beats The Street in Q1 results

Integra Lifesciences (NSDQ:IART) posted first-quarter results that beat the overall consensus on Wall Street.

The Princeton, N.J.-based surgical and medical instrument company reported profits of $32.9 million, or 39¢ per share, on sales of $376.6 million for the three months ended March 31, for a bottom-line loss of 27.5% on sales growth of 4.6% compared with Q1 2021.

Adjusted to exclude one-time items, earnings per share were 74¢, 6¢ ahead of The Street, where analysts were looking for sales of $362 million.

“I am pleased with the resilience shown by Integra colleagues as we navigated the COVID-19 Omicron wave early in the quarter,” CEO Jan De Witte said in a news release. “With global procedure volumes improving in March, our strong execution enabled us to deliver better-than-expected first-quarter revenue with organic growth exceeding 5%.”

Integra Lifescience expects reported revenues for Q2 2022 to be in the range of $392 million to $400 mill…

Read more
  • 0

Integra Lifesciences beats The Street in Q4 results

Integra Lifesciences (NSDQ:IART) today posted fourth-quarter results that beat the overall consensus on Wall Street.

The Princeton, N.J.-based surgical and medical instrument company reported profits of $45.4 billion, or 53¢ per share, on sales of $405.5 million for the three months ended Dec. 31, 2021, for a sales growth of 4.34% compared with Q4 2020.

Adjusted to exclude one-time items, earnings per share were 84¢, 1¢ ahead of The Street, where analysts were looking for sales of $403.4 million.

“Our 2021 financial performance and business achievements are a testament to our broad and differentiated product portfolio, and the resilience and commitment of our team members around the world, despite the ongoing effects of the global pandemic,” president and CEO Jan De Witte said in a news release. “I look forward to working with my Integra colleagues to continue to execute our growth priorities and accelerate our product pipeline and global opportunities i…

Read more
  • 0

12 of medtech’s biggest personnel changes in 2021

As medtech companies continued to drive innovation throughout the past 12 months, a number of high-level executives led the way.

Some of those companies and those executives opted for major changes over the course of 2021, though, with some high-profile moves from medtech giant to medtech giant.

Here are some of the biggest personnel moves in the medtech space in 2021:

Get the full story at our sister site, Medical Design & Outsourcing.

Read more
  • 0

Integra rises on Street-beating Q3, raised EPS guidance

Integra LifeSciences (NSDQ:IART) shares got a boost this morning on third-quarter results that topped the consensus forecast.

IART shares were up 5.6% at $70.95 per share in early-morning trading. MassDevice’s MedTech 100 Index — which includes stocks of the world’s largest medical device companies — was up 0.2%.

The Princeton, N.J.-based surgical and medical instrument company posted profits of $43.2 million, or 51¢ per share, on sales of $386.9 million for the three months ended Sept. 30, 2021, for a 33.7% bottom-line gain on sales growth of 4.5%.

Adjusted to exclude one-time items, earnings per share were 86¢, 14¢ ahead of Wall Street, where analysts were looking for sales of $384.6 million.

“Strength across most of our product portfolio, driven by commercial and operational execution and a contribution from our recently launched CereLink ICP monitor, led to third-quarter results near the high end of our guidance range, despite ongo…

Read more
  • 0

Integra Lifesciences announces new CEO

Incoming Integra LifeSciences CEO Jan D. De Witte [Image courtesy of Integra]Integra LifeSciences (NSDQ:IART) announced today that former Barco CEO Jan D. De Witte will take over the corner office at Integra by the end of the year.

De Witte left Barco effective September 1. He will succeed Peter J. Arduini, who is leaving Integra Lifesciences to lead GE Healthcare.

The top spot at Integra will transition by the end of the year.

Barco’s healthcare portfolio includes a host of medical displays and imaging systems. During his five years at the Kortrijk, Belgium–based company, De Witte led a turnaround that included streamlining the portfolio and strengthening the digital capabilities.

Princeton, N.J.–based Integra has a focus on regenerative tissue technologies and neurosurgical technology.

“The company has a rich history of global leadership in neurosurgery with some of the most recognized brands in plastic and reconstructive surgery…

Read more
  • 0

Integra Lifesciences raises guidance on Street-beating Q2 results

Integra LifeSciences (NSDQ:IART) today posted second-quarter results that beat the overall consensus on Wall Street.

The Princeton, N.J.-based company reported profits of $35.1 million, to 41¢ per share, on sales of $389.9 million, for the three months ended June 30, for a sales growth of 50.8% compared with Q2 2020.

Earnings per share were 79¢, 13¢ ahead of The Street, where analysts were looking for sales of $376 million.

“We are pleased with second-quarter results that exceeded our forecasts. Our business segments were well-positioned to capitalize on the improving demand driven by the ongoing global market recovery,” president and CEO Peter Arduini said in a news release.

“We saw particularly healthy order activity in products used in neurosurgery, instruments, burn, trauma and surgical reconstruction as markets gradually recovered. Areas such as capital equipment and our international indirect markets are still early in their recovery but are…

Read more
  • 0

MedTech 100 roundup: Nearing new highs once again

Having hit a downturn as the summer neared, the medtech industry is now consistently on the rise as June comes to a close.

MassDevice‘s MedTech 100 Index — which includes stocks of the world’s largest medical device companies — finished the week (June 25) at 113.42 points, producing a 2.5% rise from the 110.64-point mark set one week prior (June 18). In all, the industry has risen 5.9% over the past three weeks.

The recent upswing shows no signs of slowing after the industry’s progress came to a halt with a -1.4% dip earlier this month. The index looks set to close in on the 114.58-point mark set in April, marking the industry’s all-time best performance.

Even with some recent setbacks, medtech’s performance continues to reflect an overall rebound from the struggles brought on by the COVID-19 pandemic, too. The industry has registered a 22.9% rise from the pre-pandemic high of 92.32 (set on Feb. 19, 2020), plus a 82.6% increase from the mid-pandemic low …

Read more
  • 0

Integra Lifesciences CEO steps down to succeed GE Healthcare CEO Murphy

Integra LifeSciences (NSDQ:IART) announced today that Peter Arduini will step down as CEO to accept a new role at GE Healthcare (NYSE:GE).

Princeton, N.J.-based Integra said in a news release that Arduini will step down at the end of 2021 to assume the role of president & CEO at GE Healthcare. Current president and CEO of GE Healthcare, Kieran P. Murphy, this week expressed his intention to retire, according to a separate release.

“It has been a privilege and honor to serve as Integra’s President and CEO since 2012 and to work alongside this talented and passionate team. Together, we have accomplished much, including global leadership in neurosurgery with some of the most recognized brands in plastic and reconstructive surgery, and an innovative pipeline to accelerate future growth,” Arduini said in Integra’s release. “I want to personally thank Stuart and the Board for their invaluable guidance and unwavering partnership over the years, as well as ou…

Read more
  • 0

Integra Lifesciences ticks up before hours on Street-beating Q1 results

Integra LifeSciences (NSDQ:IART) today posted first-quarter results that beat the consensus on Wall Street.

The company reported profits of $45.4 million, or 53¢ per share, on sales of $360.1 million for the three months ended March 31, for a bottom-line gain of 394.5% sales growth of 1.62% compared with Q1 2020.

Adjusted to exclude one-time items, earnings per share were 69¢, 12¢ ahead of The Street, where analysts were looking for sales of $349.8 million.

“We are pleased with the strong start to the year, having returned to organic growth in the first quarter, despite the ongoing headwinds from COVID-19,” president and CEO Peter Arduini said in a news release. “We also expect an improvement in procedures as we move through the year, positioning Integra to achieve our 2021 financial targets.”

Integra Lifesciences said it is raiding its lower end of its full-year guidance by $5 million to a range of $1.525 billion to $1.535…

Read more
  • 0

The top 7 medtech CEO quotes on COVID-19, one year later

The latest earnings season has provided insights into the future of medtech in the COVID-19 landscape and what certain sectors are seeing as vaccines start to roll out.

Since the start of the pandemic, 113.1 million COVID-19 cases have been reported worldwide, according to Johns Hopkins University School of Medicine. The U.S. leads the world in infections, accounting for 28.4 million cases. More than 2.5 million people have died from the virus globally. Medtech has been on the frontlines throughout the pandemic, whether it was shifting production to make ventilators or PPE or developing COVID-19 tests and vaccines.

More than a year since the virus’ appearance in the U.S., some medtech CEOs are gaining a better understanding of how the industry may look moving forward. From stockpiling to new COVID-19 variants posing risks, here are the insights from seven CEOs.

Next >>
Read more
  • 0

Integra LifeSciences posts earnings beat in Q4

Integra LifeSciences (NSDQ:IART) shares dipped today despite fourth-quarter results that beat the consensus earnings forecast.

The Princeton, N.J.-based medtech company posted profits of $92.7 million, or $1.09 per share, on sales of $388.6 million for the three months ended Dec. 31, 2020, coming in well ahead of its Q4 2019 profit of $15.3 million despite a sales decline of -1.6%.

Adjusted to exclude one-time items, earnings per share were 84¢, 11¢ ahead of Wall Street, where analysts were looking for sales of $388.6 million.

Improvements in surgical procedure volumes after many delays during the COVID-19 pandemic resulted in some growth for Integra, according to a news release.

“The safety and well-being of our colleagues has remained our number one priority throughout the pandemic, so they could continue to deliver critical, life-saving products to clinicians,” Integra president & CEO Peter Arduini said in the release. “Th…

Read more
  • 0

Smith + Nephew closes Extremity Orthopedics purchase

Integra LifeSciences (NSDQ:IART) announced today that it completed the divestiture of its extremity orthopedics business to Smith+Nephew (NYSE:SNN).

The companies previously announced the planned divestiture, worth $240 million, in September 2020.

At the time, London-based Smith+Nephew said that the acquisition would significantly strengthen its extremities business by adding a combination of a focused sales channel and complimentary shoulder replacement and upper and lower extremities portfolios, plus a new product pipeline.

Integra’s commercial sales force to be inherited by Smith+Nephew focuses predominantly in the U.S. with further sales and distribution in Canada and Europe.

The inherited portfolio includes devices, implants and instruments designed for shoulder replacement and reconstruction of bone in the hand, wrist and elbow, along with the foot and ankle. Additionally, the pipeline includes a next-generation shoulder replacement system e…

Read more
  • 0